Diet Pills Market Set for Steady Growth to US$ 5.65 Billion by 2031, Led by North America's 42.8% Market Share | DataM Intelligence

Leander, Texas - The Global Diet Pills Market reached USD 3.34 billion in 2022 and is projected to reach USD 5.65 billion by 2031, growing at a steady CAGR of 6.8% during 2024-2031.

Market growth is driven by rising obesity rates, increasing consumer focus on weight management, and growing demand for safe and effective slimming solutions. Additionally, expanding product availability, lifestyle changes, and advancements in prescription and over-the-counter formulations are further accelerating market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/diet-pills-market?ram

United States: Key Industry Developments
✅ September 2025: Eli Lilly advanced its weight loss pill orforglipron, expected to be the first new oral alternative in the booming obesity treatment market, aiming for regulatory approval soon, which could significantly enhance accessibility and address supply shortages of injectable options.

✅ August 2025: Novo Nordisk prepared to launch its oral simaglutide, a pill version of its popular injectable weight loss drug, reporting patients losing about 15% of body weight in late-stage trials, awaiting US FDA decision and planning to scale production for a 2026 release.

Asia Pacific / Japan: Key Industry Developments
✅ September 2025: Eli Lilly announced plans to launch its experimental oral weight-loss drug orforglipron in India, indicating expansion into Asia Pacific markets with potentially significant market impact.

✅ Earlier in 2025: The Asia-Pacific region showed innovation and consumer base expansion in weight loss products, with a projected CAGR of 9.6% from 2025 to 2030 driven by new product launches and market growth trends.

Key Merges and Acquisitions (2025):
✅ In November 2022, Audax Private Equity, a US-based investment company, acquired Medi-Weightloss, Inc., a US company providing specialized weight-loss programs including diet pills, expanding access to care for a growing patient population.

✅ Eli Lilly announced in March 2025 plans to launch its blockbuster diabetes and weight-loss drug Mounjaro (tirzepatide) in major markets, which is part of their strategic portfolio expansion in obesity and related treatments.

✅ Pfizer made a significant acquisition in 2025 by agreeing to acquire Metsera in a competitive bid, strengthening its position in the obesity and weight management market.

Market Segmentation Analysis:
-By Source: Fruits and Vegetables lead as the preferred source of diet pills, driven by consumer preference for natural and plant-based ingredients, holding an estimated market share of around 35% in 2024. Roots and Leaves follow, supporting the herbal and traditional medicine trend.

-By Type: Prescription drugs dominate the market with approximately 43% share due to their proven efficacy and doctor recommendations. Over-the-Counter (OTC) drugs and Herbal Supplements hold significant shares of about 25% and 20% respectively, reflecting growing demand for accessible and natural options.

-By Form: Tablets represent the leading form segment with a share of about 36.3% in 2025, favored for convenience, longer shelf life, and precise dosage. Capsules and Powders come next, catering to specific user preferences.

-By Age Group: Adults constitute the largest consumer group with the highest market share driven by health consciousness and disposable income, capturing around 53%. Adolescents and children have smaller shares, reflecting product targeting and safety concerns.

-By Function: Medicinal functions hold the main share at roughly 60%, as diet pills are mostly used for therapeutic weight loss. Aroma and other functional types have niche markets.

-By Usage: Weight Loss is the principal usage segment commanding the highest market share, supported by rising obesity rates and health awareness. Body Shaping holds a smaller yet growing share.

-By Distribution Channels: Online pharmacies lead with around 53.2% share in 2025, leveraging convenience and wider product availability. Hospital and retail pharmacies follow with a collective offline dominance but lesser individual shares.

-By Application: Metabolism Raising Pills are the fastest growing segment, holding a key share driven by demand for thermogenic and energy-boosting supplements. Appetite Suppression and Fat Blocking pills also capture significant shares.

-By End-User: Adults for home use dominate the market due to self-managed weight loss trends, with hospitals and weight loss centers representing notable but smaller shares.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=diet-pills-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising global obesity rates and overweight population driving demand for effective weight management solutions.

-Increasing awareness of health risks related to obesity, such as diabetes and heart disease, motivating weight loss interventions.

-Growing focus on health and wellness and expansion of weight management services.

-Innovations in diet pill formulations and ingredients, including appetite suppressants and plant-based options.

-Increased access to healthcare and growth of e-commerce and direct-to-consumer channels.

-Personalized weight management solutions leveraging technology for tailored recommendations based on genetics or lifestyle factors.

Regional Insights:

-North America: This region dominates the global diet pills market, accounting for approximately 42.8% of the weight loss drugs market and up to 70% of the anti-obesity drugs market in 2024. The large market share is due to the high prevalence of obesity (affecting over 40% of U.S. adults), advanced healthcare infrastructure, significant R&D investments by pharmaceutical companies (like Eli Lilly and Novo Nordisk), and favorable healthcare policies that support the use of prescription weight loss medications.

-Europe: Europe holds a significant market share, driven by increasing health consciousness, government initiatives to prevent obesity, and high consumer spending on health supplements. Germany and the UK are leading markets, with strong regulations and a growing demand for clinically proven metabolic boosters. Europe generated a revenue of approximately USD 579.1 million in 2024 for diet pills.

-Asia-Pacific: The Asia-Pacific region is projected to be the fastest-growing market for diet pills and supplements, driven by rising obesity rates, increasing disposable incomes, and a cultural shift towards preventive health in countries like China and India. The region held a major share in the global market in 2024.

-Latin America: The Latin American market is witnessing steady growth, accounting for about 6.3% of the global market in 2024. Growth is fueled by rising obesity prevalence, urbanization, and a growing interest in active, healthy living. Brazil and Mexico are emerging as key markets.

-Middle East & Africa: This region represents a smaller but expanding market segment, driven by increasing healthcare investments, a growing population, and a focus on medical tourism corridors. The market growth is linked to the rising prevalence of chronic diseases and the expansion of healthcare facilities.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diet-pills-market?ram

Key Players:
Nirvasa | Applied Nutrition | Lovate Health Sciences Inc | Chong's Health Care | Healthviv | MuscleTech | Novo Nordisk A/S | Vivus LLC | Now Foods | Herbalife

Key Highlights (Top 5 Key Players) for Diet Pills Market:
-Iovate Health Sciences Inc reported approximately USD 101.3 million in market revenue in 2025.

-Nov-Nordisk A/S is a major market player, though specific 2025 revenue data for diet pills is not directly available, the company is large in the health sector.

-MuscleTech, as a recognized brand in weight management supplements, contributes significantly to the market, with broad consumer recognition but individual revenue figures specific to diet pills are not publicly detailed.

-Herbalife has substantial revenue from nutrition and weight management products globally, though exact figures specific to diet pills in 2025 are not pinpointed in accessible data.

-Applied Nutrition and Lovate Health Sciences Inc are significant players with growing market presence; Lovate was noted for strategic growth and collaborations.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.